Objectives: This study evaluated patients treated post-FDA clearance and compared real world 18-month results and complications to those seen in the pivotal 12-month FDA study .

Objectives: Review the types of acne scars as well as the pathophysiology of acne scarring.
Discuss factors affecting scar treatment.
Address available treatments with a specific focus on effective combination therapies for acne scarring.

Introduction: The pathophysiology of acne scarring is not fully understood but includes genetic predispositions, intensity and duration of inflammation, and aberrant wound healing. Eliminating Scars is unlikely and no matter the therapy, patients will need multiple treatments. Factors to be considered when determining treatment include scar type, presence of active acne, skin color of patient, cost of treatments, available downtime and patient preferences.

Materials / method: Extensive review of the literature for randomized clinical trials assessing acne scarring treatments with a focus on combination therapies.

Results: There are many types of acne scarring treatments available with no gold standard. Randomized clinical trials are limited but demonstrate that results are best with combination therapies that consider many treatment factors and must be individualized for the patient.

Conclusion: There is no gold standard acne scarring treatment. Patients should be treated early even at the first acne visit for best outcomes. It is important to treat scar associated erythema. Patient's expectations must be managed as it is difficult to eliminate scars completely. Multiple treatments are necessary that will require costs to the patient as well as downtime but success is achievable.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: the best strategies and evidence for preventing and treating scars.

Introduction: prevalence and pathogenic mechanism of the development of acne scars

Materials / method: presentation of current scientific evidence

Results: clinical cases

Conclusion: final messages on how to reduce the incidence and severity of scars

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: Efficacy and safety evaluation of a novel treatment of acne scarring using a multimodal approach comprising Dermabrasion or oxegeneo , subcision in rolling scars with microthreads network support , electronically controlled noninsulated RF microneedling system, PRP , and dermapin with hyaluronic acid highly concentrated solution , and light therapy on acne scars in patients with dark skin managing the atrophic acne scars among a sample of UAE patients

Objectives: The audience will learn the different types of atrophic scars and how to combine treatments for maximum efficacy. A focus on the longevity of HA fillers for this indication will be explored with high resolution photos and videos of the treatment and results after 2 years as shown from a controlled split face clinical trial published in Dermatologic Surgery. (Siperstein R, Nestor E, Meran S. Prospective Clinical Trial Demonstrating the Efficacy of Hyaluronic Acid Filler for the Improvement of Atrophic Facial Scars up to 2 years. Dermatol Surg. 2024 Jul 5. doi: 10.1097/DSS.0000000000004315. )

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: Allergan supplied supplies and covered some costs of the 2 year study I will be discussing

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
是
请注明名称（个人，公司，学会等等）: investigator, consultant and speaker for allergan, sciton and galderma

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。